Monopar Therapeutics files 8-K exhibit with limited discernible content
Monopar Therapeutics submitted an SEC 8-K filing with exhibit 99.1 containing minimal substantive information. Without clear filing details, market impact and company developments cannot be assessed.
View filing at SEC.gov →